Below are the most recent publications written about "Liver Neoplasms" by people in Profiles.
-
Rasic G, de Geus SWL, Beaulieu-Jones B, Kasumova GG, Kent TS, Ng SC, McAneny D, Tseng JF, Sachs TE. A nationwide propensity score analysis comparing ablation and resection for hepatocellular carcinoma. J Surg Oncol. 2023 Jun; 127(7):1125-1134.
-
Vreeland TJ, Collings AT, Ozair A, Adams AM, Dirks R, Kushner BS, Sucandy I, Morrell D, Whiteside J, Ansari MT, Cloyd J, Cleary SP, Ceppa E, Abou-Setta AM, Alseidi A, Awad Z, Ayloo S, Buell J, Orthopoulos G, Richardson W, Sbayi S, Wakabayashi G, Asbun H, Slater BJ, Pryor AD, Jeyarajah DR. SAGES/AHPBA guidelines for the use of minimally invasive surgery for the surgical treatment of colorectal liver metastases (CRLM). Surg Endosc. 2023 04; 37(4):2508-2516.
-
Nandivada P, Tirabassi M. Invited Commentary: Persistence Pays Off- Pursuing NED Status in Hepatoblastoma Improves Survival: An Observational Study by Fleming A, et?al. J Pediatr Surg. 2023 Jun; 58(6):1088-1089.
-
Mou H, Eskiocak O, ?zler KA, Gorman M, Yue J, Jin Y, Wang Z, Gao Y, Janowitz T, Meyer HV, Yu T, Wilkinson JE, Kucukural A, Ozata DM, Beyaz S. CRISPR-induced exon skipping of ?-catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer. J Pathol. 2023 04; 259(4):415-427.
-
Papageorge MV, de Geus SWL, Woods AP, Ng SC, Lee S, McAneny D, Tseng JF, Kenzik K, Sachs TE. ASO Visual Abstract: Surveillance Patterns for Hepatocellular Carcinoma Among Screening-Eligible Patients in the Medicare Population. Ann Surg Oncol. 2022 12; 29(13):8434-8435.
-
Ozair A, Collings A, Adams AM, Dirks R, Kushner BS, Sucandy I, Morrell D, Abou-Setta AM, Vreeland T, Whiteside J, Cloyd JM, Ansari MT, Cleary SP, Ceppa E, Richardson W, Alseidi A, Awad Z, Ayloo S, Buell JF, Orthopoulos G, Sbayi S, Wakabayashi G, Slater BJ, Pryor A, Jeyarajah DR. Minimally invasive versus open hepatectomy for the resection of colorectal liver metastases: a systematic review and meta-analysis. Surg Endosc. 2022 Nov; 36(11):7915-7937.
-
Papageorge MV, de Geus SWL, Woods AP, Ng SC, Lee S, McAneny D, Tseng JF, Kenzik KM, Sachs TE. Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population. Ann Surg Oncol. 2022 Dec; 29(13):8424-8431.
-
Schneider KM, Mohs A, Gui W, Galvez EJC, Candels LS, Hoenicke L, Muthukumarasamy U, Holland CH, Elfers C, Kilic K, Schneider CV, Schierwagen R, Strnad P, Wirtz TH, Marschall HU, Latz E, Lelouvier B, Saez-Rodriguez J, de Vos W, Strowig T, Trebicka J, Trautwein C. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. Nat Commun. 2022 07 08; 13(1):3964.
-
Hickman TL, Choi E, Whiteman KR, Muralidharan S, Pai T, Johnson T, Parikh A, Friedman T, Gilbert M, Shen B, Barron L, McGinness KE, Ettenberg SA, Motz GT, Weiss GJ, Jensen-Smith A. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS One. 2022; 17(5):e0266980.
-
Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncol. 2022 Feb; 18(6):739-748.